Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, China.
Department of Nuclear Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, China.
Front Endocrinol (Lausanne). 2024 Oct 15;15:1433553. doi: 10.3389/fendo.2024.1433553. eCollection 2024.
It is well established that patients with the most differentiated thyroid cancers have a good prognosis, whereas when the disease develops into radio-iodine refractory thyroid cancer (RAIR) their prognosis is poor and the 10-year survival rate is low. At present, the therapeutic methods for RAIR are limited and have low efficacy. As a consequence, several models have been developed for predicting RAIR. The aim of this review was to describe recent developments regarding the factors that influence and predict the occurrence of RAIR. Many variables including demographic characteristics, tumor clinicopathology, serology changes, disease characteristics, and PET/CT results have been shown to be independent factors that influence the development of RAIR. The cut-off value derived from multivariate prediction models therefore effectively predicts the onset of RAIR. However, the current models for predicting RAIR were obtained through retrospective studies, and the prospective prediction studies are needed in the future to confirm their validity.
众所周知,分化型甲状腺癌患者预后良好,而当疾病发展为放射性碘难治性甲状腺癌(RAIR)时,其预后较差,10 年生存率较低。目前,RAIR 的治疗方法有限,疗效不佳。因此,已经开发了几种预测 RAIR 的模型。本综述的目的是描述影响和预测 RAIR 发生的因素的最新进展。许多变量,包括人口统计学特征、肿瘤临床病理学、血清学变化、疾病特征和 PET/CT 结果,已被证明是影响 RAIR 发展的独立因素。因此,多变量预测模型得出的截止值可有效预测 RAIR 的发生。然而,目前预测 RAIR 的模型是通过回顾性研究获得的,未来需要前瞻性预测研究来验证其有效性。